organoid

As the FDA shifts toward nonclinical methods, scientists weigh whether alternative technologies can match the predictive power of animal studies.

As nearly 90 percent of drugs fail in human trials, researchers are turning to patient-derived cells, engineered tissues, and AI to better predict human responses and reduce costly late-stage failures.

Explore how advanced functional human organ models improve preclinical drug testing and toxicity evaluation.

From virtual control groups to brain organoids, new approach methodologies are transforming how drugs and cosmetics are tested for safety.

Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 

Harnessing human-first models to accelerate drug discovery, improve safety, and capture the diversity of human biology.

Mini “miBrains” replicate key brain cell types, enabling personalized disease research and drug testing.

The updated brand identity underscores nearly 30 years of scientific leadership and a growing portfolio designed for modern preclinical discovery.

The kidney structures replicate newborn-level maturity, enabling studies of complex disease features such as fibrosis and drug toxicity.

Refining organoid culture methods is key to creating lifelike models for drug discovery, cancer research, and therapy testing.